Detection of minimal residual disease (MRD) has prognostic value in many hematologic
malignancies, including acute lymphoblastic leukemia, acute myeloid leukemia, chronic …

Large-scale clinical studies on detection of minimal residual disease (MRD) in acute
lymphoblastic leukemia (ALL) have shown that quantification of MRD levels is needed for …

Minimal residual disease (MRD) diagnostics has proven to be clinically relevant for
evaluation of treatment effectiveness in patients with acute lymphoblastic leukemia (ALL). In …

Abstract Analysis of minimal residual disease (MRD) can predict outcome in acute
lymphoblastic leukemia (ALL). A large prospective study in childhood ALL has shown that …

PCR of clonally rearranged immunoglobulin heavy chain (IgH) gene sequences is
increasingly used for detection of minimal residual disease (MRD) in lymphoid …

Real-time quantitative RT-PCR (RQ-PCR) is a sensitive tool to monitor minimal residual
disease (MRD) in leukemic patients through the amplification of a fusion gene (FG) …

Quantification of residual disease by real-time polymerase chain reaction (PCR) will become
a pivotal tool in the development of patient-directed therapy. In recent years, various …

Detection of minimal residual disease (MRD) can be useful for adaptation or stratification of
treatment in acute leukemia patients and may finally result in individualization of treatment …

Monitoring minimal residual disease (MRD) becomes increasingly important in the risk-
adapted management of patients with acute myeloid leukemia (AML). The two most …

The detection of minimal residual disease (MRD) using immunoglobulin and T-cell receptor
(TCR) rearrangements as PCR targets provides important prognostic information on the in …